Nov 4, 2024 · Information about Moderna COVID-19 Vaccine, Bivalent. Updated, bivalent mRNA COVID-19 vaccines are now FDA-authorized for all doses for individuals ages 6 months and older.

In January 2021, Moderna started development of a new form of its vaccine, called mRNA-1273.351, that could be used as a booster shot against the Beta variant (lineage B.1.351). [ 195 ] [ 186 ] In February 2021, Moderna announced that it had manufactured and shipped sufficient amounts of mRNA-1273.351 to the National Institutes of Health to run ...

Sep 16, 2024 · Moderna COVID-19 vaccine 2024-2025 formula is authorized for people ages 6 months through 11 years. Spikevax is approved for people age 12 and older. The vaccines that help protect against COVID-19 are safe and effective based …

Aug 28, 2024 · Moderna COVID-19 Vaccine 2024-2025 Formula is indicated for people 6 months through 11 years of age. Moderna SPIKEVAX ® is indicated for people 12 years and older

Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single)...

Messenger RNA (mRNA) already exists in your body. It carries a “message” - instructions that direct your cells what to do. mRNA medicines fight diseases in a different way than traditional medicine by prompting your immune system to create the tools to treat or prevent disease.

Moderna COVID-19 Vaccine At-A-Glance Guidance below summarizes basic storage, preparation, scheduling, administration, and dosage for all 2024–25 Moderna COVID-19 vaccine products. Distributed in: Ages: 6 months through 11 years Manufacturer-filled syringe Ages: 12 years and older Manufacturer-filled syringe Storage and Handling

CAMBRIDGE, MA / January 17, 2025 / Moderna, Inc. (NASDAQ: MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA ...

For adults aged 17 and above, SAGE recommends the use of the Moderna mRNA-1273 vaccine at a schedule of two doses (100 µg, 0.5 ml each) 8 weeks apart. For adolescents aged 12 to 17 years, SAGE recommends 2 doses (100 µg, 0.5 ml each), given intramuscularly, 4 weeks apart.

Jan 17, 2025 · In addition, Moderna will design and test an H7N9 mRNA pandemic influenza vaccine in a phase 3 clinical study. If successful, this vaccine potentially could become the first licensed for H7N9. Moderna also will design up to four additional novel pandemic influenza vaccines and test preliminary safety and immunogenicity (generating an immune ...